SRN 002

Drug Profile

SRN 002

Alternative Names: Intranasal migraine therapeutic - Sirenade; SRN-002

Latest Information Update: 26 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KeyNeurotek AG
  • Developer KeyNeurotek Pharmaceuticals AG
  • Class Small molecules
  • Mechanism of Action Serotonin 1B receptor antagonists; Serotonin 1D receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 15 Jul 2004 SRN 002 will be available for licensing after the successful completion of phase II trials(http://www.sirenade.biz)
  • 15 Jul 2004 Phase-II clinical trials in Migraine in Germany (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top